Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2011 by Taipei Medical University WanFang Hospital.
Recruitment status was:  Recruiting
Information provided by:
Taipei Medical University WanFang Hospital Identifier:
First received: June 8, 2010
Last updated: April 22, 2011
Last verified: April 2011
FLT3 overexpression in acute myeloid leukemia (AML) is often caused by mutations in this gene. These mutations cause constitutive phosphorylation of FLT3 proteins leading to increased proliferation and survival, decreased apoptosis and resistance to chemotherapeutic agents in AML cells. There are two major types of FLT3 mutations- internal tandem duplication (ITD) and point mutation at 835th amino residue. AMLs with FLT3 mutations have worse prognosis and are often resistant to conventional chemotherapy. Several small molecule compounds targeting FLT3 have been in the market or in clinical trials. Therefore, identification of these mutations at the time of diagnosis will provide a better prognostic prediction, might guide the treatment selection and follow-up strategies. In this study, the investigators will develop a sensitive molecular assay to detect FLT3 mutations for future clinical application. The investigators will collect 100 AML samples with at least 20 samples with known FLT3 mutations. The investigators will compare this assay with commonly used methods and standardize the procedure to meet the requirement of clinical pathology laboratory with reasonable cost.

Acute Myeloid Leukemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia

Resource links provided by NLM:

Further study details as provided by Taipei Medical University WanFang Hospital:

Biospecimen Retention:   Samples With DNA

Estimated Enrollment: 100
Study Start Date: June 2010
Estimated Study Completion Date: June 2011

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
acute myeloid leukemia patient in wanfang hospital

Inclusion Criteria:

  • Patients with confirmed diagnosis of acute myeloid leukemia

Exclusion Criteria:

  • non
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01141673

Taipei Medical University - WanFang Hospital
Taipei, Taiwan
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Principal Investigator: Hsin-Gjin Eugene Liu Taipei Medical University WanFang Hospital
  More Information

Responsible Party: Hsingjin Eugene Liu, MD PhD, Taipei Medical University WanFang Hospital Identifier: NCT01141673     History of Changes
Other Study ID Numbers: FLT3-ITD KIT 
Study First Received: June 8, 2010
Last Updated: April 22, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
acute myeloid leukemia

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms processed this record on December 02, 2016